Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.81
11% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
WARRANT
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.8K | $2.5M | $9.4M | $6.2M |
| Cost of revenue | $40.3K | $22.2K | $4.8K | $467 | $1.7M | $6.0M | $4.7M |
| Gross profit | −$40.3K | −$22.2K | −$4.8K | $4.3K | $791.6K | $3.4M | $1.4M |
| Gross margin | — | — | — | 90.3% | 31.3% | 36.1% | 23.2% |
| R&D | $1.9M | $1.6M | $1.1M | $1.5M | $1.7M | $1.8M | $2.1M |
| Operating income | −$3.1M | −$2.6M | −$2.2M | −$4.0M | −$8.0M | −$9.0M | −$10.6M |
| EBITDA | −$3.0M | −$6.9M | −$5.3M | −$5.6M | −$7.6M | −$8.3M | −$14.3M |
| Net income | −$3.3M | −$7.3M | −$6.3M | −$8.2M | −$7.9M | −$9.0M | −$14.9M |
| Net margin | — | — | — | -169771.2% | -313.5% | -96.6% | -242.0% |
| EPS (diluted) | -13.50 | -29.70 | -69.57 | -54.30 | -27.30 | -22.50 | -8.66 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-8.10 | $-8.10–$-8.10 | 1 |
Forward consensus · source: Financial Modeling Prep
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
www.bioaffinitytech.comNo one on the platform currently holds BIAFW.
No tracked institution reports a position in BIAFW as of their last filing.
No one on the platform has traded BIAFW yet.
| -8.68% |
| $27M |
| — |
| NOTVInotiv, Inc. | $0.08 | +121.94% | $3M | — |
| PRPOPrecipio, Inc. | $24.73 | +1.87% | $44M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.0× sales vs its 0.0× historical median P/S.
Fair value ≈ $0.78 · price $0.14 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.